Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

What happened: Climb Bio (Nasdaq: CLYM) presented initial PrisMN Phase 2 data at ASN Kidney Week 2026 showing low dose (200 mg) budoprutug produced B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks in pMN. Key numbers: Mean PLA2R antibody reduction of 70% at Week 12; five of 13 Why it matters: The company said results build on Phase 1b findings and support evaluating higher doses, with the 600 mg cohort showing greater exposure and deeper B-cell depletion. A separate MCD case reported three-year steroid-free remission, supporting further investigation. Market: -3.3% today ($10.19), +171.7% YTD, 0.5x vol — as of 22:46 UTC

Climb Bio (Nasdaq: CLYM) presented initial PrisMN Phase 2 data at ASN Kidney Week 2026 showing low dose (200 mg) budoprutug produced B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks in pMN.

The company said results build on Phase 1b findings and support evaluating higher doses, with the 600 mg cohort showing greater exposure and deeper B-cell depletion. A separate MCD case reported three-year steroid-free remission, supporting further investigation. Market: -3.3% today ($10.19), +171.7% YTD, 0.5x vol — as of 22:46 UTC